Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 March 2018 Photo Earl Coetzee
Research focus on HIV and TB stigma among healthcare workers
Posters reading, “Let’s Stop Stigma” urge healthcare workers to ”Be kind to yourself. Be kind to others.” Pictured here are Dr Asta Rau, Director of CHSR&D and Dr Michelle Engelbrecht, deputy director of the centre.

Researchers working on an internationally funded project are tackling a key occupational health issue: HIV and TB stigma among Free State healthcare workers. They developed and rolled out interventions to decrease stigma and will soon measure the effects. 
In this four-year project, UFS researchers from the Centre for Health Systems Research and Development (CHSR&D) are partnering with Antwerp University and the Free State Department of Health.  

Stigma is like an invisible mark 
A project leader at the CHSR&D, Dr Asta Rau, says most research on stigma in public health focuses on HIV stigma towards patients. Little is done on stigma among healthcare workers themselves. 
Dr Rau says that stigma undermines people’s dignity and causes them suffering. It can even stop them from seeking healthcare. Stigma threatens the health of healthcare workers and the stability of the health system, which is already under strain due to personnel shortages. 

Interventions to make a difference

The research identified two types of stigma - external stigma that can be seen around us, e.g. in the way healthcare workers speak about or treat one another and internal stigma that happens when healthcare workers take this ‘outside’ stigma and turn it inward on themselves. 

Dr Rau says the interventions involve training healthcare workers about what stigma is and how to go about reducing it. “We give them the knowledge and tips on how to communicate when they encounter stigma. It is up to them to then use that to fight stigma.” A communication campaign with posters and branded social marketing materials supports the training. The campaign uses a single slogan: ”Let’s Stop Stigma” and urges healthcare workers to ”Be kind to yourself. Be kind to others."

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept